HIGHLIGHTS
- who: Michiel S. Heijden from the Barts Cancer Institute Queen Mary University of East, Chiba, Japan have published the research work: Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial, in the Journal: NATURE COMMUNICATIONS NATURE COMMUNICATIONS of 16/03/2022
- what: The authors report results from a retrospective analysis of the RANGE study using a comprehensive biomarker approach of PD-L1 status, tumor microenvironment gene_expression signatures, and molecular subtyping, to identify patients who may optimally benefit from ramucirumab therapy for UC. The authors investigated PD-L1 expression, analyzed immune . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.